Wintjens, D
310  Ergebnisse:
Personensuche X
?
1

P594 One-year success rates of targeted therapy in Ulcerati..:

Creemers, R ; van Andel, E ; Wintjens, D.
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1156-i1157 , 2024
 
?
2

P503 The risk of mild, moderate and severe infections in IB..:

Rezazadeh Ardabili, A ; van Esser, D ; Wintjens, D...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i631-i634 , 2023
 
?
3

P132 Detection and monitoring of IBD based on faecal volati..:

Bosch, S ; Wintjens, D ; Wicaksono, A...
Journal of Crohn's and Colitis.  13 (2019)  Supplement_1 - p. S154-S154 , 2019
 
?
4

P784 The direct healthcare costs of Crohn's disease increas..:

Lalisang, R ; Wintjens, D ; Romberg-Camps, M...
Journal of Crohn's and Colitis.  12 (2018)  supplement_1 - p. S507-S508 , 2018
 
?
5

DOP052 Vedolizumab vs. ustekinumab for Crohn's disease: com..:

Biemans, V ; van der Woude, C ; van der Meulen - de Jong, A...
Journal of Crohn's and Colitis.  12 (2018)  supplement_1 - p. S066-S067 , 2018
 
?
6

DOP034 Assessment of direct healthcare cost drivers of Croh..:

Lalisang, R ; Wintjens, D ; Romberg-Camps, M...
Journal of Crohn's and Colitis.  12 (2018)  supplement_1 - p. S054-S055 , 2018
 
?
7

OP002 Assessment of disease activity patterns during the fi..:

Wintjens, D ; Bergey, F ; Saccenti, E...
Journal of Crohn's and Colitis.  12 (2018)  supplement_1 - p. S001-S003 , 2018
 
1-15